Clinical Trials Logo

Clinical Trial Summary

Researchers are looking for a better way to treat heart failure (HF), a condition in which the heart does not pump blood as well as it should. Research has shown that the levels of a hormone called N-terminal proBNP (NT-proBNP) in the body can be used for differential diagnosing of HF. NT-proBNP is released by the heart when there is an increase in heart pressure. The levels of NT-proBNP can indicate whether medical problems are likely to happen due to HF. These medical problems are called "decompensation events." The higher a person's NT-proBNP levels is expected, the higher their risk of developing HF and having decompensation events. So, the researchers in this study want to learn about NT-proBNP levels and decompensation events in German patients with a common type of HF called heart failure with reduced ejection fraction (HFrEF). In patients with HFrEF, the muscle on the left chamber of the heart does not pump blood as well as it should. The researchers will collect information from patients and their health records for about 300 adult patients in Germany with HFrEF who have been receiving standard of care treatment for their condition. Standard of care treatments are treatments that doctors commonly use to treat patients. The researchers will study and record the levels of NT-proBNP levels and any changes in the health of the patients at time of NT-proBNP measurement. The researchers will collect this information between May 2021 and September 2021. The patients in this study : - have had any HF-decompensation event since January 2016 - have had at least 1 NT-proBNP measurement done before the study The researchers will collect the following information about the patients: - the results of NT-proBNP measurements - the date of the NT-proBNP measurements - the number and type of decompensation events


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04915118
Study type Observational
Source Bayer
Contact
Status Completed
Phase
Start date June 17, 2021
Completion date November 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT03456856 - A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction. Phase 4
Completed NCT03901729 - A Trial to Study BAY1753011 in Patients With Congestive Heart Failure Phase 2
Completed NCT02301689 - SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register
Completed NCT02200822 - Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients Phase 4
Recruiting NCT04149743 - HEMOTAG® Assessment for Short-term Outcomes of Heart Failure N/A
Recruiting NCT05652218 - REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT) N/A
Completed NCT02127307 - Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up. N/A
Completed NCT01936649 - Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView. Phase 4